**Table S5 Continuous *a priori* subgroup analyses.** β is the slope derived from meta-regression analyses and represents the treatment effect of oat β-glucan for each subgroup for A. LDL-C, B. Non-HDL-C, and C. ApoB. The residual I2 value indicates heterogeneity unexplained by the subgroup and is reported as a percent value, where I2 ≤ 50% indicated “moderate” heterogeneity, I² ≥ 50% indicated “substantial” heterogeneity, and ≥ 75% indicated “considerable” heterogeneity. P-value significance for heterogeneity was set as P < 0.10. N = number of participants in each treatment group.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **A. LDL-C** |   |   |   |   |   |
| Subgroups | No. of Trials | N | β [95% CI] | Residual I2 (%) | *P*-value |
| Oat B-Glucan Dose (g/day) | 57 | 3745 | -0.001 [-0.020, 0.018] | 73.85 | 0.883 |
| Duration (weeks) | 57 | 3745 | 0.012 [-0.003, 0.027] | 71.92 | 0.124 |
| Baseline LDL-C (mmol/L) | 48 | 2097 | -0.089 [-0.149, -0.029] | 69.87 | 0.004 |
|   |   |   |   |   |   |
| **B. Non-HDL-C** |   |   |   |   |   |
| Subgroups | No. of Trials | N | β [95% CI] | Residual I2 (%) | *P*-value |
| Oat B-Glucan Dose (g/day) | 57 | 3926 | -0.001 [-0.033, 0.030] | 99.16 | 0.930 |
| Duration (weeks) | 57 | 3926 | 0.007 [-0.021, 0.035] | 99.18 | 0.625 |
| Baseline Non-HDL-C (mmol/L) | 49 | 2138 | -0.080 [-0.180, 0.021] | 99.24 | 0.119 |
|   |   |   |   |   |   |
| **C. ApoB** |   |   |   |   |   |
| Subgroups | No. of Trials | N | β [95% CI] | Residual I2 (%) | *P*-value |
| Oat B-Glucan Dose (g/day) | 16 | 1070 | 0.002 [-0.007, 0.012] | 41.35 | 0.607 |
| Duration (weeks) | 16 | 1070 | -0.006 [-0.022, 0.008] | 38.86 | 0.387 |
| Baseline ApoB (g/L) | 9 | 370 | -0.008 [-0.068, 0.052] | 55.30 | 0.757 |